{"name":"Betta Pharmaceuticals Co., Ltd.","slug":"betta-pharmaceuticals-co-ltd","ticker":"","exchange":"","domain":"betta.com","description":"","hq":"New Haven","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":7,"colorKey":"immunology","drugs":[{"name":"Icotinib plus WBRT","genericName":"Icotinib plus WBRT","slug":"icotinib-plus-wbrt","indication":"Non-small cell lung cancer with EGFR mutations and brain metastases (in combination with whole-brain radiotherapy)","status":"marketed"},{"name":"Maintenance icotinib","genericName":"Maintenance icotinib","slug":"maintenance-icotinib","indication":"Maintenance therapy for locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR mutations","status":"marketed"},{"name":"Sequential Icotinib Plus Chemotherapy","genericName":"Sequential Icotinib Plus Chemotherapy","slug":"sequential-icotinib-plus-chemotherapy","indication":"Non-small cell lung cancer with EGFR mutations","status":"marketed"},{"name":"BPI-16350","genericName":"BPI-16350","slug":"bpi-16350","indication":"Cholangiocarcinoma with FGFR2 fusion or rearrangement","status":"phase_3"},{"name":"Icotinib Hydrochloride Tablets","genericName":"Icotinib Hydrochloride Tablets","slug":"icotinib-hydrochloride-tablets","indication":"Non-small cell lung cancer","status":"phase_2"},{"name":"Icotinib with concurrent radiotherapy","genericName":"Icotinib with concurrent radiotherapy","slug":"icotinib-with-concurrent-radiotherapy","indication":"Non-small cell lung cancer","status":"phase_2"},{"name":"Sequential and maintenance icotinib","genericName":"Sequential and maintenance icotinib","slug":"sequential-and-maintenance-icotinib","indication":"Non-small cell lung cancer (NSCLC) with EGFR mutations","status":"marketed"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"oncology","drugs":[{"name":"1.0% Icotinib hydrochloride cream","genericName":"1.0% Icotinib hydrochloride cream","slug":"1-0-icotinib-hydrochloride-cream","indication":"Other","status":"phase_1"},{"name":"2-year treatment with icotinib","genericName":"2-year treatment with icotinib","slug":"2-year-treatment-with-icotinib","indication":"Other","status":"phase_2"},{"name":"Chemoradiotherapy","genericName":"Chemoradiotherapy","slug":"chemoradiotherapy","indication":"Other","status":"phase_2"},{"name":"D-0316 Capsule","genericName":"D-0316 Capsule","slug":"d-0316-capsule","indication":"Phase 2 clinical trial for treatment of unspecified condition","status":"phase_2"}]}],"pipeline":[{"name":"1.0% Icotinib hydrochloride cream","genericName":"1.0% Icotinib hydrochloride cream","slug":"1-0-icotinib-hydrochloride-cream","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Icotinib plus WBRT","genericName":"Icotinib plus WBRT","slug":"icotinib-plus-wbrt","phase":"marketed","mechanism":"Icotinib is an EGFR tyrosine kinase inhibitor that blocks epidermal growth factor receptor signaling in cancer cells, combined with whole-brain radiotherapy (WBRT) to treat brain metastases.","indications":["Non-small cell lung cancer with EGFR mutations and brain metastases (in combination with whole-brain radiotherapy)"],"catalyst":""},{"name":"Maintenance icotinib","genericName":"Maintenance icotinib","slug":"maintenance-icotinib","phase":"marketed","mechanism":"Icotinib is a small-molecule tyrosine kinase inhibitor that selectively blocks epidermal growth factor receptor (EGFR) signaling to inhibit tumor cell proliferation.","indications":["Maintenance therapy for locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR mutations"],"catalyst":""},{"name":"Sequential Icotinib Plus Chemotherapy","genericName":"Sequential Icotinib Plus Chemotherapy","slug":"sequential-icotinib-plus-chemotherapy","phase":"marketed","mechanism":"Icotinib is an EGFR tyrosine kinase inhibitor that blocks epidermal growth factor receptor signaling, used sequentially with chemotherapy to treat EGFR-mutant lung cancer.","indications":["Non-small cell lung cancer with EGFR mutations"],"catalyst":""},{"name":"2-year treatment with icotinib","genericName":"2-year treatment with icotinib","slug":"2-year-treatment-with-icotinib","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"BPI-16350","genericName":"BPI-16350","slug":"bpi-16350","phase":"phase_3","mechanism":"BPI-16350 is a selective inhibitor of fibroblast growth factor receptor (FGFR) that blocks aberrant FGFR signaling in cancer cells.","indications":["Cholangiocarcinoma with FGFR2 fusion or rearrangement","Other FGFR-altered solid tumors"],"catalyst":""},{"name":"Chemoradiotherapy","genericName":"Chemoradiotherapy","slug":"chemoradiotherapy","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"D-0316 Capsule","genericName":"D-0316 Capsule","slug":"d-0316-capsule","phase":"phase_2","mechanism":"D-0316 Capsule is a small molecule that targets the molecular target.","indications":["Phase 2 clinical trial for treatment of unspecified condition"],"catalyst":""},{"name":"Icotinib Hydrochloride Tablets","genericName":"Icotinib Hydrochloride Tablets","slug":"icotinib-hydrochloride-tablets","phase":"phase_2","mechanism":"Tyrosine kinase inhibitor","indications":["Non-small cell lung cancer"],"catalyst":""},{"name":"Icotinib with concurrent radiotherapy","genericName":"Icotinib with concurrent radiotherapy","slug":"icotinib-with-concurrent-radiotherapy","phase":"phase_2","mechanism":"Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor","indications":["Non-small cell lung cancer"],"catalyst":""},{"name":"Sequential and maintenance icotinib","genericName":"Sequential and maintenance icotinib","slug":"sequential-and-maintenance-icotinib","phase":"marketed","mechanism":"Icotinib is a small-molecule tyrosine kinase inhibitor that selectively blocks epidermal growth factor receptor (EGFR) signaling to inhibit tumor cell proliferation.","indications":["Non-small cell lung cancer (NSCLC) with EGFR mutations"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxNOXFHaFhGNDk2UzJRMEtJM3p1NnZuYmlFOXJ6Q3FfQmJFWDBCM2JWRDREdFlmSkxlWHdFZV9ad0syU0cydUJpaXNpdzgwSktjTk14YklCS05JOEhiSjhyaHpaOFRUTWdXajZZRUE1ZU4xUi1CWW52S3d6b1lqRzkzcmFVdFVQeE1Mb0R5NlctVU9HNXkxTWpuaERfaE5hM2NXMlRjdFBaVTZNcmRqR2JBeUx3b1ZUTlktVjZZTXJTcWcwQQ?oc=5","date":"2026-03-31","type":"pipeline","source":"Markets Mojo","summary":"Betta Pharmaceuticals Hits Day High with Strong 5.61% Intraday Surge - Markets Mojo","headline":"Betta Pharmaceuticals Hits Day High with Strong 5.61% Intraday Surge","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-01-27","type":"deal","source":"ET HealthWorld","summary":"Beta Drugs Limited set to acquire 66.09% stake in Nivian Lifesciences Private Limited - ET HealthWorld","headline":"Beta Drugs Limited set to acquire 66.09% stake in Nivian Lifesciences Private Limited","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxQaWFGSXRIZGRjRWE4YVRTT0FiT1VBYUxscm9abWRLc0w5bmZGUzZfQ0U3Q3dlOVI1aFZlQ3BEY2J4MUlzeUtGNzRBeGhXUUc5TVYzT2R3ZWxqLWFzSElDYmI1VzBFN216SG5OMW5VRHpuUmVYcUN6QU43dHhuREtabEV0dlZ0cWJhU1I4?oc=5","date":"2026-01-12","type":"deal","source":"Law.asia","summary":"Cooley advises Jacobio’s USD2bn licensing deal with AstraZeneca - Law.asia","headline":"Cooley advises Jacobio’s USD2bn licensing deal with AstraZeneca","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2AFBVV95cUxNWDFqU25uWE54bDI3WmVOR1pkZDAyS0ZYNXdCbVJ1czVnU3BvQUV2dnlkMlloVjFvOTZpWjZnZF9GczFJS0c1YUVUUWNFb3N0R1Qyb0xQcTdPNWdCZUo3NUJIQ1lhMUxId0NjNzdqX09jdGo3NEtvSUVnRU5OX1JuNE9zbjJEMDFxdnJUR1JHZ2hQYUVDQlFsZ1RrMG1NQVZzcWNqTXhuOXdMREFiUmRXTzduYzdUdEtNZlRuOTJsQzQxTEs1N3QtNWxYdVNTa1RvNm5RdEVJZXA?oc=5","date":"2026-01-12","type":"deal","source":"scanx.trade","summary":"Beta Drugs Acquires 66% Stake in IVF Specialist Nivian Lifesciences for ₹69.4 Crore - scanx.trade","headline":"Beta Drugs Acquires 66% Stake in IVF Specialist Nivian Lifesciences for ₹69.4 Crore","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgJBVV95cUxOb3J5ak1QUkRhMEs0VGFkNEpad2tNOEtkS2gtRjAzVWQ2a1BKQkpnS2xZUXM2TlQ0b1JfcTIzUzZxNWVZNWhTUjJaQTZkOWZSREtmaVNXNXFMQWFrNXJSa3prOWZxMVJMRTE5Z3NibEdYaHFKYUw5d2I3Z1ozRXdiV3RXN0p5ZTVDVEJ6TjRrTko2N2dmQzJDV19ZM1dsbUdnQTRUM3ZwaXJDdi1GVTRMcWdGTHg3NDY5a2g1ajZudVBtYWdSQmY4Qk4wN0U4bFl1LXB1Z0Z3N1dOR3BJWjlNZzE1MzVNQTRlcWFEU2hQb3ZFbU9zWlQwNV9mdGZZQ05zM2FxLVZoc2Z3YjJ2VmJQQ2kxS2pDQ0c2cWRGMS10S25zVm9wd0E?oc=5","date":"2025-10-01","type":"pipeline","source":"Business Wire","summary":"JCR Pharmaceuticals Announces Licensing Agreement with Menagen to Commercialize Agalsidase Beta BS I.V. Infusion [JCR] Across Nine MENAT Markets - Business Wire","headline":"JCR Pharmaceuticals Announces Licensing Agreement with Menagen to Commercialize Agalsidase Beta BS I.V. Infusion [JCR] A","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxPdkVkRlRrcW1zSXRubjQxOFQwY0k0R0hQSl9fMWpwdG1SWUlzR0NNQjhJelYzMHhKWS1mSVFEamktdVFEMGJDRk5tRTdYVTB5Y1RlbFFxV3pSVTNmMWtxYlhJMlYzdHNsRlN6UUlhZmdCdWZzcnYwdGlNWlc2SEV1VGlkRllCdmtlVlRxX1dlRnVoY3Z2WFB6TzVlSXNVSi1wT212QjVSMlRJMHlFMXgwdHJHWQ?oc=5","date":"2025-09-29","type":"pipeline","source":"moomoo.com","summary":"IPO News | Betta Pharmaceuticals (300558.SZ) Submits Listing Application to HKEX, Successfully Transformed into a 'Platform-Based Pharmaceutical Enterprise' - moomoo.com","headline":"IPO News | Betta Pharmaceuticals (300558.SZ) Submits Listing Application to HKEX, Successfully Transformed into a 'Platf","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxPWmV0QkYyMUlGdUVkamJhMTF6d2Q2ak1FNlUtcUN4anVzZTRmd2lFa1VrRkhMTkdkNG11bUxrNjZ3TnBPak5ROFhQNGFucGhTT05KUTNld3JsNWdhVUtYVTRoWGhqcjZqZHF0WnZ5NTF4bmczM3FnM0pTU0tpb3ZVTGtyT3F1bnJkR2tYRnRpZFRvVUdmSVpZcVgzS1dsOUdiZ2o2Y3h4U04?oc=5","date":"2025-07-24","type":"pipeline","source":"International Finance Corporation (IFC)","summary":"Answering Africa’s Call for Private Investment in Pharma Manufacturing - International Finance Corporation (IFC)","headline":"Answering Africa’s Call for Private Investment in Pharma Manufacturing - International Finance Corporation (IFC)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxOdE1PeEdGcDZYMURsU19waml2Q0pQT2JpT1dwRXRmdXBSS3JKNDc5eHpIQ1BLUVFIMU5WcDFxTXVsOXdUbl9ySko1MlRlZWJuM2NyMS1LSTY0cWRJVnZBX0dzQzk5OG1IcUJ4QkxEV2syNzNGYVQza0JDOFN2WURwb0NDUlAzeDlGa1NpYW13aFpnazJtWUVJRl9QZ0k5MUR1MVgzbnRWcUp1alNQd2l3ZFRB?oc=5","date":"2025-05-14","type":"pipeline","source":"BioWorld News","summary":"Integrating antibody therapy and oncolytic virotherapy enhances effects - BioWorld News","headline":"Integrating antibody therapy and oncolytic virotherapy enhances effects","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxPLW40cXZ3elBLal90Q3hpS1FwU0VzdmZGUWRFc3FIR1BOZ0w2cHlTbmkyb1pSYjE0R3hIX2pYZm9YWnh1UHczXzh6WWRQU3VsU2lkRWZhdXZCUmlLOHlTT0lVeS1HeEZnVjRiQU9HQ2hkM21BTlRkR2oxMUZ3aGJZMVlGcndWV3hqWHY2aDRZamdqVWtXeUhsanQ0UU85RjlJcVB3U1pFbWtBTGNnUVE?oc=5","date":"2024-12-19","type":"regulatory","source":"Fierce Pharma","summary":"Playing catch-up with Pfizer and Roche, China-made ALK drug clears FDA in lung cancer - Fierce Pharma","headline":"Playing catch-up with Pfizer and Roche, China-made ALK drug clears FDA in lung cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxNcDB4ZFl0OElQSjNHd0x4NTRqSXdVMlZfVkxLRlZnYk4wZzZnSl81YVlaWDEySXh6OGxIdzRrNUNXVDhXM2lFdnlRdlRkQTdGTFVvcmlXNDQ1dllZSGt0N21HUWdfZDdCSnRfMUI0Z1ZkdWVocWlLZGdteGo0bTFaV001TGdVbDNsVGpERHZDc2Z0OHc1UzlYam9TOXJIV29TWWc5UjRWUXQ?oc=5","date":"2024-11-04","type":"pipeline","source":"drugdiscoverytrends.com","summary":"Roche, Novartis lead 2024’s top 50 pharma in oncology (YTD) - drugdiscoverytrends.com","headline":"Roche, Novartis lead 2024’s top 50 pharma in oncology (YTD)","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2023-05-30","type":"pipeline","source":"GlobeNewswire","summary":"C4 Therapeutics and Betta Pharmaceuticals Announce - GlobeNewswire","headline":"C4 Therapeutics and Betta Pharmaceuticals Announce","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_gFBVV95cUxPeEdVMzUwTHhqSEJ4OE9PTjNTM3cxNzdPcjdUYlROZEd5dVg5VTBxdGMyUzdDYjR6UEhsOWpzVTFSaVBBQTVwN21qR1Z0dUVoSW9xMFppWkxCYlByQVZLanJGZ2RkMGw1S1dzSG9Udm1nX3VjMDJCZElyX20zV2R1MXpKOEdvbndKSTJ0U3RFcjkyem10b2Vnd0hyT05qb3hJM1c0WjQzdGhjVC1kU3NRcDQ1Y09XcnZvbU93a3ZoaVdqTjItTFFOUUw4Tnc0NnZjcmw4WUxMWlF2NnlPM3AtYTItNUhHUjFsU1dtTTVMVXFocVVpd0phZlBWbWFfdw?oc=5","date":"2020-06-22","type":"deal","source":"PR Newswire","summary":"Agenus and Betta Pharmaceuticals Enter Into a License Agreement for Balstilimab and Zalifrelimab in Greater China - PR Newswire","headline":"Agenus and Betta Pharmaceuticals Enter Into a License Agreement for Balstilimab and Zalifrelimab in Greater China","sentiment":"neutral"}],"patents":[],"drugCount":11,"phaseCounts":{"phase_1":1,"marketed":4,"phase_2":5,"phase_3":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}